<DOC>
	<DOCNO>NCT00872729</DOCNO>
	<brief_summary>Cystinosis inheritable disease untreated , result kidney failure early first decade life . The current marketed therapy Cystagon® ( cysteamine bitartrate ) must take every six hour rest patient 's life prevent complication cystinosis . RP103 formulation cysteamine bitartrate study see may able give less frequently , every 12 hour , similar result .</brief_summary>
	<brief_title>Pilot Study Safety , Tolerability , Pharmacokinetics/Pharmacodynamics RP103 Compared Cystagon® Patients With Cystinosis</brief_title>
	<detailed_description>This single-dose , open-labeled , non-randomized , two-period study Cysteamine Bitartrate Delayed-release Capsules ( RP103 ) Cystagon® 10 patient ( male female ) nephropathic cystinosis fast condition . It involve 4 night check-in clinical research center .</detailed_description>
	<mesh_term>Cystinosis</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>Male female subject must nephropathic cystinosis . Children le 22.5 kg include study investigator feel safely participate study include require blood draw volume safety PK/PD assessment . Subjects must stable dose Cystagon® least 21 day prior Screening . Subjects must able swallow 150 mg Cystagon® capsule capsule intact . Within last 2 month , clinically significant change liver function [ i.e. , ALT , AST , alkaline phosphatase , bilirubin ( total direct ) ] renal function [ i.e. , serum creatinine , albumin , total protein ] Screening determine Investigator . Sexually active female subject childbearing potential ( i.e. , surgically sterile [ tubal ligation , hysterectomy , bilateral oophorectomy ] least 2 year naturally postmenopausal ) must agree utilize acceptable form contraception screen completion study . Subjects authorize caregiver must provide write informed consent assent ( applicable ) prior participation study . If opinion investigator , patient safely provide study require blood draw volume . Subjects must willing able comply study restriction requirement . If , opinion investigator , plan study dose would exceed patient 's tolerability cysteamine base prior Cystagon® steady state drug requirement . Evidence verbal attestation Helicobacter pylorus infection , presently , within last 90 day prior Screening . Subjects know history , currently within past 90 day prior Screening , follow condition health issue make , opinion investigator , unsafe participate , whose concomitant medical problem preclude commit study schedule include following : Crohn 's disease , inflammatory bowel disease ( currently active ) prior resection small intestine ; • History heart disease , e.g. , myocardial infarction , heart failure , arrhythmias ; Any bleed disorder ; Malignant disease ; Severe liver disease define ALT AST &gt; 2 time upper limit normal . Subjects kidney transplant . Subjects plan registered candidate kidney transplant within 3 month Screening serum creatinine &gt; 2.4 . Subjects know hypersensitivity cysteamine . If female ( childbearing potential ) , nursing , plan pregnancy , know suspected pregnant , positive urine pregnancy screen . Patients hemoglobin level &lt; 10.5 . Subjects make blood donation within 60 day prior study initiation . Subjects , opinion Investigator , able willing comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>cystinosis</keyword>
	<keyword>cysteamine</keyword>
	<keyword>inheritable disease</keyword>
	<keyword>orphan disease</keyword>
	<keyword>CTNS protein , human</keyword>
	<keyword>nephropathic cystinosis</keyword>
</DOC>